Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Palliative Care × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Stress Disorders, Post-Traumatic 1 Prostatic Neoplasms 1 Penile Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Malignant Solid Neoplasm 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Kidney Neoplasms 1 Inflammatory Breast Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Agnosia 1

Interventions

pembrolizumab 73 Carboplatin 63 Pemetrexed 54 Cisplatin 40 Paclitaxel 35 durvalumab 23 Specimen Handling 23 Nivolumab 19 Magnetic Resonance Spectroscopy 18 Gemcitabine 17 osimertinib 14 Docetaxel 14 Bevacizumab 13 130-nm albumin-bound paclitaxel 12 atezolizumab 11 Cetuximab 10 cemiplimab 9 Taxes 9 Radiotherapy 9 Immunoglobulin G 9 Drug Therapy 9 Radiosurgery 8 Disulfides 8 Biopsy 8 tislelizumab 7 amivantamab 7 Observation 7 Fluorouracil 7 Oxaliplatin 6 Leucovorin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07467863 2026-03-12

DUO-NK-NSCLC

Beijing Biotech

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡